0001819790-24-000045.txt : 20240319 0001819790-24-000045.hdr.sgml : 20240319 20240319190506 ACCESSION NUMBER: 0001819790-24-000045 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240315 FILED AS OF DATE: 20240319 DATE AS OF CHANGE: 20240319 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Azamian Bobak R. CENTRAL INDEX KEY: 0001827672 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39614 FILM NUMBER: 24765687 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD, SUITE 160 CITY: IRVINE STATE: CA ZIP: 92618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001819790 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 814717861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: (949) 409-9820 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 4 1 wk-form4_1710889492.xml FORM 4 X0508 4 2024-03-15 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001827672 Azamian Bobak R. C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618 1 1 0 0 President/CEO and Board Chair 0 Common Stock 2024-03-15 4 M 0 28274 A 36871 D Common Stock 2024-03-18 4 S 0 10415 30.60 D 26456 D Common Stock 830106 I By the Bobak Azamian Living Trust established April 16, 2018 Restricted Stock Units 2024-03-15 4 M 0 11299 0 D Common Stock 11299 22599 D Restricted Stock Units 2024-03-15 4 M 0 16975 0 D Common Stock 16975 50925 D The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Each RSU represents a contingent right to receive one share of the Issuer's common stock. RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service. RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2024, March 15, 2025, March 15, 2026 and March 15, 2027, subject to the Reporting Person's continuous service. /s/ Jeffrey Farrow, Attorney-in-Fact 2024-03-19